ADReCS

Pharmaceutical Information

Drug Name	Capecitabine
Drug ID	BADD_D00349
Description	Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage	For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status	approved; investigational
ATC Code	L01BC06
DrugBank ID	DB01101
KEGG ID	D01223
MeSH ID	D000069287
PubChem ID	60953
TTD Drug ID	D00HCQ
NDC Product Code	55111-893; 82920-001; 72205-007; 72485-205; 62331-043; 16714-467; 51407-640; 55111-496; 55111-497; 61269-475; 65162-844; 15308-0714; 54893-0002; 59651-205; 64980-277; 70756-815; 68001-487; 69097-949; 72205-006; 63482-099; 72969-094; 16729-072; 59923-721; 61269-470; 0054-0271; 69539-019; 0093-7473; 64980-276; 0054-0272; 69097-948; 72606-554; 53104-7618; 55512-0015; 0004-1100; 51407-639; 67877-459; 68001-488; 69539-020; 35369-0010; 16729-073; 51407-096; 62756-238; 62756-239; 65162-843; 67877-458; 59651-204; 72485-204; 72606-555; 49452-1713; 68554-0033; 0004-1101; 0093-7474; 51407-095; 60687-149; 0378-2511; 70756-816; 53183-4009; 54245-7014; 65129-1241; 81955-0001; 16714-468; 59923-722
UNII	6804DJ8Z9U
Synonyms	Capecitabine \| N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine \| Xeloda

Chemical Information

Molecular Formula	C15H22FN3O6
CAS Registry Number	154361-50-9
SMILES	CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Breast cancer stage IV	21.05.01.010; 16.10.01.003	0.000112%		Not Available
Bronchitis	22.07.01.001; 11.01.09.001	-	-
Bronchospasm	22.03.01.004; 10.01.03.012	0.000951%
Bundle branch block left	02.03.01.007	0.000392%		Not Available
Burning sensation	17.02.06.001; 08.01.09.029	0.007880%		Not Available
Cachexia	14.03.02.001; 16.32.03.011; 08.01.01.009	0.000168%		Not Available
Cardiac arrest	02.03.04.001	0.003358%
Cardiac failure	02.05.01.001	-	-
Cardio-respiratory arrest	22.02.06.007; 02.03.04.002	0.001735%		Not Available
Cardiogenic shock	24.06.02.006; 02.05.01.003	0.000728%		Not Available
Cardiomyopathy	02.04.01.001	0.001086%		Not Available
Cataract	06.06.01.001	-	-
Cellulitis	23.11.02.004; 11.02.01.001	-	-	Not Available
Cerebellar ataxia	17.02.02.013; 08.01.02.006	0.000224%		Not Available
Cerebellar infarction	24.04.06.007; 17.08.01.013	0.000112%		Not Available
Cerebral atrophy	17.11.01.001	0.000112%		Not Available
Cerebral ischaemia	24.04.06.003; 17.08.01.005	0.000392%
Cerebral venous thrombosis	24.01.04.005; 17.08.03.002	0.000336%		Not Available
Cerebrovascular accident	24.03.05.001; 17.08.01.007	-	-
Change of bowel habit	07.02.03.002	-	-	Not Available
Cheilitis	23.03.03.025; 07.05.01.001	0.000358%
Chest discomfort	02.02.02.009; 22.12.02.002; 08.01.08.019	0.002843%		Not Available
Chest pain	22.12.02.003; 08.01.08.002; 02.02.02.011	0.007980%		Not Available
Chills	15.05.03.016; 08.01.09.001	-	-
Cholangiocarcinoma	09.04.02.009; 16.07.01.002	0.000112%		Not Available
Cholangitis	09.02.01.002	0.000616%		Not Available
Cholecystitis	09.03.01.001	0.001242%
Cholecystitis acute	09.03.01.003	0.000224%		Not Available
Cholestasis	09.01.01.001	0.000616%		Not Available
Chromaturia	20.02.01.002	0.001041%

The 3th Page First Pre 3 4 5 6 7 Next Last Total 31 Pages